Table Graph
      published meta-analysis   sensitivity analysis   studies

Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.20 [0.02; 1.72] 0.20[0.02; 1.72]ChAdOx1 phase 3 (AstraZeneca), 202010%11,636NAnot evaluable symptomatic Covid-19detailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.26; 0.43] 0.33[0.26; 0.43]ChAdOx1 phase 3 (AstraZeneca), 202010%17,177NAnot evaluable asymptomatic COVID casedetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.23; 0.48] 0.33[0.23; 0.48]ChAdOx1 phase 3 (AstraZeneca), 202010%11,636NAnot evaluable infection (PCR positive symptomatic or not)detailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.44 [0.33; 0.59] 0.44[0.33; 0.59]ChAdOx1 phase 3 (AstraZeneca), 202010%11,636NAnot evaluable severe COVID-19 occurrencedetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.02; 14.54] 0.49[0.02; 14.54]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable vaccine efficacy after dose 1 (and before dose 2)detailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.24 [0.14; 0.41] 0.24[0.14; 0.41]ChAdOx1 phase 3 (AstraZeneca), 202010%18,494NAnot evaluable serious adverse eventsdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.86 [0.64; 1.17] 0.86[0.64; 1.17]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Bell's palsydetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.98 [0.20; 4.83] 0.98[0.20; 4.83]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable immediate allergic reactiondetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.07; 58.15] 1.95[0.07; 58.15]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable multiple sclerosisdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.07; 58.15] 1.95[0.07; 58.15]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable myelitisdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.18; 21.52] 1.95[0.18; 21.52]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Gastrointestinal disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.03; 3.13] 0.33[0.03; 3.13]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Musculoskeletal disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.98 [0.06; 15.60] 0.98[0.06; 15.60]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Neuroinflammatory disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 1.22 [0.33; 4.54] 1.22[0.33; 4.54]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Skin disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.73 [0.16; 3.27] 0.73[0.16; 3.27]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Vasculitidesdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.02; 14.54] 0.49[0.02; 14.54]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Thromboembolic eventsdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.15; 1.62] 0.49[0.15; 1.62]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2025-10-31 07:25 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 759 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons